Trial reportMetabolism: clinical and experimental2011
Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects.
Trial report in Metabolism: clinical and experimental, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.Diabetes, obesity & metabolism · 2020Trial
- Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes.The New England journal of medicine · 2020Trial
- Circulating cytokines as determinants of weight loss-induced improvements in insulin sensitivity.Endocrine · 2017 · on this mapTrial
- Optimal exercise modality and dose for reducing visceral adipose tissue in overweight or obese adults: a network meta-analysis and dose-response study.BMC sports science, medicine & rehabilitation · 2026Article
- Chaihu-Wendan Decoction alleviates obesity through PTEN-mediated uncoupling of metabolic signaling and macrophage activation.Frontiers in endocrinology · 2026Article
- Conservatively Treated Mesenteric Vein Thrombosis in a 48-Year-Old Obese Female: A Case Report.Cureus · 2023Article
- Islet amyloid polypeptide does not suppress pancreatic cancer.Molecular metabolism · 2023Article
- Multi-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks.Endocrine reviews · 2021Review
- Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes.Current diabetes reports · 2020Review
- Non-insulin determinant pathways maintain glucose homeostasis upon metabolic surgery.Cell discovery · 2018Article
- Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis.European journal of pediatrics · 2017Article
- Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation.Journal of Cancer · 2016Review
- Triglycerides produced in the livers of fasting rabbits are predominantly stored as opposed to secreted into the plasma.Metabolism: clinical and experimental · 2015Article
- Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.American journal of physiology. Endocrinology and metabolism · 2015Article
- Adiponectin as a tissue regenerating hormone: more than a metabolic function.Cellular and molecular life sciences : CMLS · 2014Review
- Metabolic alterations following visceral fat removal and expansion: Beyond anatomic location.Adipocyte · 2012Article
- Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.Gastroenterology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
Abstract
Low systemic plasma adiponectin concentrations are associated with abnormalities in hepatic glucose and lipoprotein metabolism in obese people. However, the relationship between the delivery of adiponectin to the liver via the portal vein and hepatic glucose and lipoprotein metabolism is not known. We examined the relationship between hepatic substrate metabolism (glucose rate of appearance into plasma and hepatic very low-density lipoprotein [VLDL]-triglyceride [TG] and VLDL-apolipoprotein B-100 [apoB-100] secretion rates, determined by using stable isotope-labeled tracer techniques) and portal vein adiponectin concentration, in 8 insulin-resistant, extremely obese subjects (body mass index, 65 ± 7 kg/m(2)). Portal vein adiponectin concentration was inversely associated with basal glucose rate of appearance (r = -0.820, P = .013) and VLDL-TG (r = -0.823, P = .012) and VLDL-apoB-100 (r = -0.787, P = .020) secretion rates. Very similar correlations were obtained for radial artery adiponectin as a result of a mirroring relationship between portal and arterial adiponectin concentrations (r = 0.899, P = .002) and the absence of significant arteriovenous concentration differences (P = .570). Insulin resistance, assessed with the homeostasis model assessment score, was also strongly associated with hepatic glucose and lipid metabolic parameters, as well as with adiponectin concentrations in the portal vein and radial artery. These results suggest that adiponectin delivery to the liver, whether via the portal or the systemic circulation, may be an important regulator of basal hepatic glucose, VLDL-TG, and VLDL-apoB-100 production rates in obese people, possibly through direct effects on the liver or changes in hepatic insulin sensitivity. However, portal vein adiponectin does not appear to be superior to arterial adiponectin as a marker of hepatic metabolic dysregulation. Additional studies are needed to elucidate the mechanism(s) responsible for the strong association we observed between adiponectin and hepatic substrate metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.